Epiminder (ASX:EPI) Total Receivables: A$1.03 Mil (As of Dec. 2025)


ASX:EPI Epiminder Ltd ASX:EPI
17 GF Score
Price A$0.32
View Full Analysis

What is Epiminder Total Receivables?

Epiminder ASX:EPI +1.59% 17 Total Receivables is A$1.03 Mil as of Dec. 2025. GuruFocus rates ASX:EPI with a GF Score™ of 17/100.

Epiminder's Total Receivables for the quarter that ended in Dec. 2025 was A$1.03 Mil.

Epiminder Total Receivables Historical Data

* Premium members only.

The historical data trend for Epiminder's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epiminder Total Receivables Chart

Epiminder Annual Data
Trend Jun23 Jun24 Jun25
Total Receivables
0.00 0.00 0.38

Epiminder Semi-Annual Data
Jun23 Jun24 Jun25 Dec25
Total Receivables 0.00 0.00 0.38 1.03
ASX:EPI
17GF Score
Epiminder Ltd ASX:EPI
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Epiminder Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$1.03 Mil mean?
Epiminder (ASX:EPI) has a Total Receivables of A$1.03 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Epiminder and its competitors.
Is Epiminder's Total Receivables too high?
Epiminder's current Total Receivables is A$1.03 Mil. Overall, Epiminder has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Epiminder's Total Receivables compare to ABT and SYK?
Epiminder's Total Receivables of A$1.03 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Epiminder and its competitors. Epiminder's current Total Receivables is A$1.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epiminder stock overvalued right now?
Epiminder (ASX:EPI) has a current Total Receivables of A$1.03 Mil. The current Total Receivables is A$1.03 Mil. Epiminder's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Epiminder (ASX:EPI), the current Total Receivables is A$1.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Epiminder Business Description

Address 525 Collins Street, 210 West Podium, Mezzanine 2, Melbourne, VIC, AUS, 3000
Epiminder Ltd is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy. Its system is a sub-scalp device for continuous monitoring of electrographic brain activity and a set of information solutions, providing patients and their healthcare professionals with detailed data over an extended period.
17GF Score

Get the complete analysis for ASX:EPI

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.32
Price